Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00623428 · ClinicalTrials.gov registry record · Phase 3

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

A Phase 3 study of Hepatitis C, Chronic, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 3
Development phase
235
Enrollment target
20
Study locations

NCT00623428 is a Phase 3 study of Hepatitis C, Chronic that has completed, run by Hoffmann-La Roche. The registered enrollment target is 235 participants, below the 367-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00623428, a Phase 3 study of Hepatitis C, Chronic, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 3
Development phase
235 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.

Conditions Studied

Hepatitis C, Chronic

Interventions

  • DRUG Ribavirin
  • DRUG peginterferon alfa-2a

Study Locations (20)

California

  • - La Jolla
  • - Lancaster
  • - Long Beach
  • - Los Angeles
  • - Los Angeles
  • - Sacramento
  • - Sacramento
  • - San Diego
  • - Torrance

Florida

  • - Jacksonville
  • - Orlando

Georgia

  • - Atlanta
  • - Marietta

Louisiana

  • - Baton Rouge
  • - Opelousas

Alabama

  • - Birmingham

Colorado

  • - Aurora

Hawaii

  • - Honolulu

Massachusetts

  • - Boston

Trial Details

FieldValue
Enrollment Target 235 participants
Start Date 2008-06
Est. Completion 2012-05
Phase Phase 3

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00623428

The ClinicalTrials.gov registry entry for NCT00623428 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 367-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (36% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Ribavirin is the first listed.

NCT00623428 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00623428 about?

NCT00623428 is a clinical study titled "A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response". This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.

What is the current status of trial NCT00623428?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 235 participants. The study started on 2008-06. Estimated completion is 2012-05.

What conditions does trial NCT00623428 study?

This clinical trial studies the following conditions: Hepatitis C, Chronic.

What interventions are being tested in trial NCT00623428?

The interventions under investigation include: Ribavirin (DRUG), peginterferon alfa-2a (DRUG).

Who is sponsoring clinical trial NCT00623428?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00623428 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C, Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C, Chronic

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.